Nanomedicine Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

Friday, November 3, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Nov. 2, 2017 /PRNewswire/ --

Nanomedicine Market by Modality (Treatments and Diagnostics), Application (Drug

Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, and Others), and Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Disorders, Neurological Diseases, Urological Diseases, Ophthalmological
Diseases, Immunological Diseases, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023Download the full report: is a branch of medicine that uses tools and knowledge of nanotechnology for prevention and treatment of different diseases. Nanomedicines are multifunctional drugs with programmable properties that find applications in monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. These nanomedicines have the potential to revolutionize the current scenario of detection of disease, its treatment, and diagnosis methods. The global nanomedicine market accounted for $111,912 million in 2016, and is anticipated to reach $261,063 million by 2023, registering a CAGR of 12.6% from 2017 to 2023.The global nanomedicine market is driven by emerging innovative technologies for drug delivery, advantages of nanomedicine in various healthcare applications, rise in government support and funding, and growth in need for safe and cost-effective therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are anticipated to provide numerous opportunities for the market growth.The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. Based on indication, it is categoried into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopaedic disorders, immunological diseases, cardiovascular diseases, and others. On the basis of modality, it is bifurcated into treatments and diagnostics.Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in the global market, owing to increase in presence of stronger players focussed on R&D activities and commercialization of nanomedicines in the region. In addition, this region leads in the number of nanotechnology patent applications resulting in higher demand in the market. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, owing to the rapid development of healthcare infrastructure and growth in health awareness among the middle-class population.The key players operating in the global market have focused on expanding their presence in the nanomedicine sector. Moreover, new players moving into healthcare contribute by expanding expertise range, leveraging diversification, and augmenting scale by providing the necessary capital for the nanomedicine development.KEY BENEFITS FOR STAKEHOLDERSThe study provides an in-depth analysis of the global nanomedicine market and the current trends and future estimations to elucidate the imminent investment pockets.The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.Extensive analysis of the market based on product assists to understand the trends in the industry.Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.KEY MARKET SEGMENTSBy ApplicationDrug DeliveryVaccinesDiagnostic ImagingRegenerative MedicineImplantsOthersBy ModalityDiagnosticsTreatmentsBy IndicationOncological DiseasesInfectious DiseasesCardiovascular DiseasesOrthopedic DisordersNeurological DiseasesUrological DiseasesOphthalmological DiseasesImmunological DiseasesOthersBy RegionNorth AmericaU.S.CanadaMexicoEuropeGermanyFranceUKItalySpainRest of EuropeAsia-PacificJapanChinaIndiaAustraliaRest of Asia-PacificLAMEABrazilArgentinaSaudi ArabiaSouth AfricaRest of LAMEAKEY PLAYERS PROFILEDAbbott LaboratoriesCombiMatrix CorporationGeneral electric CompanySigma-Tau Pharmaceuticals, Inc.Johnson & JohnsonMallinckrodt plc.Merck & Company, Inc.Nanosphere, Inc.Pfizer, Inc.Teva Pharmaceutical Industries Ltd.The other players in the value chain include (profiles not included in the report)Celgene CorporationUCB (Union Chimique Belge) S.A.AMAG PharmaceuticalsNanospectra Biosciences, Inc.Arrowhead Pharmaceuticals, Inc.Leadiant Biosciences, Inc.Epeius Biotechnologies CorporationGileadCytimmune Sciences, Inc.NanoCarrierLTT BioPharmaMebiopharmDownload the full report: About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email: Tel: +44 208 816 85 48 Website:


View original content:

SOURCE ReportBuyer


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store